title: Intra-arterial chemotherapy less intensive than RADPLAT with concurrent radiotherapy for resectable advanced head and neck squamous cell carcinoma: a prospective study.
abstract: OBJECTIVE
  This study was designed to evaluate the efficacy and feasibility of our intra-arterial chemotherapy protocol with a lower amount and frequency of cisplatin delivery than in RADPLAT for the treatment of resectable advanced head and neck cancer.
  
  
  METHODS
  Fifty-one patients with advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were included in this prospective study. The patients were treated with 3 courses of cisplatin (100 mg at 1 treatment, intra-arterial) and sodium thiosulfate (28 g at 1 treatment, intravenous) once every 2 weeks during concurrent radiotherapy (66 to 70 Gy, 2 Gy per fraction, daily for 5 days over 7 weeks). Nodal metastases larger than 3 cm in diameter were treated with an additional 50 mg of cisplatin. The patients with less than 50% tumor reduction after 40 Gy and 2 courses of chemotherapy were treated with surgery.
  
  
  RESULTS
  The protocol was completed for 49 patients. All living patients had a minimum follow-up period of 2 years. Including the 3 patients with salvage surgery, local disease-free control was achieved in 39 patients (80%). For 36 patients (73.5%), disease-free primary organs were preserved at 2 years after treatment. Locoregional disease-free control for 2 years was obtained for 38 patients (77.6%), in 30 of them without salvage surgery. The patients treated with surgery had an overall survival rate similar to that of the patients with a complete response (80% and 84.6%, respectively). The patients with a partial response had a worse prognosis (40%; p = .0069).
  
  
  CONCLUSIONS
  This treatment regimen is feasible and effective for advanced resectable head and neck cancer.
authors.affiliation: Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan.
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Yoshizaki
authors.forename: Naohiro
authors.initials: N
authors.lastname: Wakisaka
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Murono
authors.forename: Satoru
authors.initials: S
authors.lastname: Kondo
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takanaka
authors.forename: Jun-ichiro
authors.initials: J
authors.lastname: Sanada
authors.forename: Noboru
authors.initials: N
authors.lastname: Terayama
authors.forename: Osamu
authors.initials: O
authors.lastname: Matsui
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Furukawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013885:Thiosulfates; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D013885:Thiosulfates; C017717:sodium thiosulfate; D002945:Cisplatin